Douglas to keep it in the family after considering bids
This article was originally published in Scrip
Companies looking to expand their presence in New Zealand through acquisitions can strike off their lists of prospects the most obvious target - the country's largest home-grown pharma firm, Douglas Pharmaceuticals.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.